ダウンロード数: 5424

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
57_671.pdf2.2 MBAdobe PDF見る/開く
タイトル: 尿路上皮癌に対するCisplatin(CDDP)を含む化学療法施行時の腎機能評価方法の比較検討
その他のタイトル: Impact of Different Methods of Estimating Renal Function on Determining Eligibility for Cisplatin (CDDP)-Based Chemotherapy in Patients with Invasive Urothelial Carcinoma
著者: 後藤, 崇之  KAKEN_name
吉村, 耕治  KAKEN_name
松井, 喜之  KAKEN_name
清水, 洋祐  KAKEN_name
井上, 貴博  KAKEN_name
大久保, 和俊  KAKEN_name
神波, 大己  KAKEN_name
西山, 博之  KAKEN_name
小川, 修  KAKEN_name
著者名の別形: Goto, Takayuki
Yoshimura, Koji
Matsui, Yoshiyuki
Shimizu, Yosuke
Inoue, Takahiro
Okubo, Kazutoshi
Kamba, Tomomi
Nishiyama, Hiroyuki
Ogawa, Osamu
キーワード: Urothelial carcinoma
Renal function
Side effects
発行日: Dec-2011
出版者: 泌尿器科紀要刊行会
誌名: 泌尿器科紀要
巻: 57
号: 12
開始ページ: 671
終了ページ: 676
抄録: Assessment of renal function is important to determine the appropriate dose for cisplatin (CDDP)-based chemotherapy. Many previous CDDP-based chemotherapy trials for bladder cancer have required a creatinine-clearance (Ccr) ≧60 ml/min for entry. However, there is little evidence on renal function assessed by estimated glomerular filtration rate (eGFR) using the 4-variable Modification of Diet in Renal Disease Study Equation (MDRD), which has recently been introduced, to determine the eligibility for CDDP-based chemotherapy. To evaluate the proportion of patients with invasive urothelial carcinoma(UC) who would be ineligible (“unfit”) to receive CDDP-based chemotherapy based on eGFR criteria (eGFR <60 ml/min/1.73 m2), and to determine the side effects of chemotherapy in these “unfit” patients, we conducted a retrospective clinical study. Our study population consisted of 61 consecutive patients who underwent 100% dose CDDP-based chemotherapy for invasive UC with 24 h-Ccr≧50 ml/min between June 2001 and July 2009. We assessed renal function using 3 equations (eGFR, Ccr according to Cockcroft-Gault formula (C-G Ccr), and Ccr examined by 24-hour urine collection (24 h-Ccr)) as well. Mean values of eGFR, C-G Ccr, and 24 h-Ccr were 58.6, 68.9, and 82.8 ml/min, respectively (P< 0.001). In total, 29/61(48%) patients were ineligible (“unfit”) to receive chemotherapy based on eGFR criteria. However, there was no difference in the frequency of side effects between eGFR ≧60 ml/min/ 1.73 m2 and eGFR <60 ml/min/1.73 m2 groups. Our observations suggest that 24 h-Ccr≧50 ml/min would be a reasonable cutoff for CDDP-based chemotherapy even when eGFR <60 ml/min/1.73 m2.
著作権等: 許諾条件により本文は2013-01-01に公開
URI: http://hdl.handle.net/2433/152317
PubMed ID: 22240299
出現コレクション:Vol.57 No.12

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。